Bank of New York Mellon
ALZN icon

Bank of New York Mellon’s Alzamend Neuro ALZN Stock Holding History

Bank of New York Mellon’s Portfolio ALZN Stock Details ALZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-30
Closed -$9.57K – 4310
2023
Q3 		$9.57K Hold
30
– – ﹤0.01% 4301
2023
Q2 		$20.6K Hold
30
– – ﹤0.01% 4288
2023
Q1 		$17.2K Hold
30
– – ﹤0.01% 4323
2022
Q4 		$22.8K Buy
+30
New +$43.4K ﹤0.01% 4341

Other funds holding ALZN

Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
RA
RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
HIA
Harbor Investment Advisory Lutherville, Maryland $1.43B AUM 30.71% 1-Year Est. Return

Bank of New York Mellon's ALZN Position: Q4 2023 in Review

Bank of New York Mellon sold out of Alzamend Neuro (ALZN) in Q4 2023, closing a stake of 30 shares — an estimated $9.57K sold.

Bank of New York Mellon first reported a position in ALZN in Q4 2022 and held it in 4 quarters. The position peaked at $22.8K in Q4 2022. 14 funds tracked by Wall St. Rank hold ALZN as of Q4 2023.

  • Bank of New York Mellon reported no remaining Alzamend Neuro position as of Q4 2023 after selling out during the quarter.
  • Bank of New York Mellon sold 30 Alzamend Neuro shares in Q4 2023, an estimated $9.57K.
  • Bank of New York Mellon first reported a position in Alzamend Neuro in Q4 2022 and held it in 4 quarters.
  • Bank of New York Mellon's Alzamend Neuro position peaked at $22.8K in Q4 2022.
  • 14 funds tracked by Wall St. Rank held Alzamend Neuro as of Q4 2023.

Based on Bank of New York Mellon's 13F filing for Q4 2023, filed 29 Jan 2024.